Taysha Gene Therapies, Inc. (TSHA)
| Market Cap | 411.94M |
| Revenue (ttm) | 9.92M |
| Net Income (ttm) | -22.77M |
| Shares Out | 204.94M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,013,096 |
| Open | 2.120 |
| Previous Close | 2.120 |
| Day's Range | 1.960 - 2.120 |
| 52-Week Range | 1.190 - 4.320 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 6.63 (+229.85%) |
| Earnings Date | Nov 13, 2024 |
About TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of ang... [Read more]
Financial Performance
In 2023, Taysha Gene Therapies's revenue was $15.45 million, an increase of 517.55% compared to the previous year's $2.50 million. Losses were -$111.57 million, -32.80% less than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TSHA stock is "Strong Buy." The 12-month stock price forecast is $6.63, which is an increase of 229.85% from the latest price.
News
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Thursday.
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director and Head, Investor Relations Sean Nolan - Chie...
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (hig...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Taysha Gene Therapies' TSHA-102 shows promising results for Rett syndrome, leveraging miRARE technology to modulate MECP2 expression, improving patients' quality of life in Phase 1/2 trials. TSHA-102'...
Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encoura...
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for ...
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday.
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for ...
What's Going On With Taysha Gene Therapies Stock Tuesday?
Tuesday, Taysha Gene Therapies Inc TSHA released longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric tr...
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safe...
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU...
Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Rela...
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrol...
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and ...
Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024. Cohort 1 data of...
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained impro...
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based...
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company's request to initiate dose escalation; dosing of first patient in...
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-ba...
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t...